Aggressive Lymphoma after CD19 CAR T-Cell Therapy
Guido Kobbe, Monika Brüggemann, Ben‐Niklas Baermann, Laura Wiegand, Heiko Trautmann, Schayan Yousefian, Silvana Libertini, Hans D. Menssen, Harald J. Maier, Peter Ulrich, Jingbo Gao, Peter‐Martin Bruch, Nora Liebers, Aleksandar Radujkovic, Marc Seifert, Christina Schniederjohann, Nagarajan Paramasivam, Donnacha Fitzgerald, Maximilian Seidel, Iréne Esposito, Ulrich Germing, Ron‐Patrick Cadeddu, Kathrin Nachtkamp, Paul Jäger, Thomas Ulrych, Johannes Fischer, Jutta M. Rox, Frederik L. Giesel, Raphael Koch, Gerald Antoch, Jörg H. W. Distler, Sven G. Meuth, Malte Jacobsen, Daniel Hübschmann, Junyan Lu, Ingram Iaccarino, Simon Haas, Frédérik Damm, Sascha Dietrich
Abstract
mutation, which was already detectable in the CAR T-cell apheresis product and the final CAR T-cell product at very low frequencies, providing evidence that clonal hematopoiesis had contributed to lymphomagenesis.